Insmed Incorporated (INSM)
| Market Cap | 22.36B +87.1% |
| Revenue (ttm) | 819.56M +115.1% |
| Net Income | -1.18B |
| EPS | -5.70 |
| Shares Out | 216.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,282,941 |
| Open | 106.09 |
| Previous Close | 106.91 |
| Day's Range | 102.87 - 106.37 |
| 52-Week Range | 69.59 - 212.75 |
| Beta | 0.89 |
| Analysts | Strong Buy |
| Price Target | 200.00 (+93.87%) |
| Earnings Date | May 7, 2026 |
About INSM
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 ... [Read more]
Financial Performance
In 2025, Insmed's revenue was $606.42 million, an increase of 66.73% compared to the previous year's $363.71 million. Losses were -$1.28 billion, 39.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for INSM stock is "Strong Buy." The 12-month stock price target is $200.0, which is an increase of 93.87% from the latest price.
News
Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
BRIDGEWATER, N.J., May 27, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform ...
Insmed Transcript: RBC Capital Markets Global Healthcare Conference 2026
Strong quarterly growth and operational execution support a $1B+ revenue target, with high payer approval and patient retention. Market expansion is driven by education, new patient identification, and robust pipeline progress, including ARIKAYCE and TPIP.
Insmed Slides: Investor presentation
Insmed has posted slides in relation to its latest quarterly earnings report, which was published on May 16, 2026.
Insmed files automatic mixed securities shelf
17:07 EDT Insmed (INSM) files automatic mixed securities shelf
Insmed price target lowered to $185 from $205 at Truist
Truist lowered the firm’s price target on Insmed (INSM) to $185 from $205 and keeps a Buy rating on the shares. The firm updated its model following Q1 results, incorporating…
Insmed Transcript: AGM 2026
The meeting established a quorum and proceeded with the election of two directors, approval of executive compensation, and ratification of the auditor. All proposals passed with no shareholder questions submitted.
Insmed Transcript: Bank of America Global Healthcare Conference 2026
BRINSUPRI's launch is exceeding expectations with strong sales, high physician engagement, and expanding market size. Pipeline progress, especially with TPIP, and disciplined research investments position the company for sustained growth and future profitability.
Insmed earnings selloff a buying opportunity, says H.C. Wainwright
H.C. Wainwright views the post-earnings selloff in shares of Insmed (INSM) as a buying opportunity. The “core Brinsupri launch thesis remains intact,” the analyst tells investors in a research note.
Insmed price target lowered to $185 from $200 at Raymond James
Raymond James lowered the firm’s price target on Insmed (INSM) to $185 from $200 and keeps an Outperform rating on the shares.
Insmed Earnings Call Transcript: Q1 2026
BRINSUPRI delivered exceptional sequential growth and is on track for $1B+ in 2026 revenue, with strong payer access, high compliance, and expanding prescriber base. ARIKAYCE and TPIP also advanced, while robust cash reserves support continued execution and pipeline growth.
Insmed Quarterly report: Q1 2026
Insmed has published its Q1 2026 quarterly earnings report on May 7, 2026.
Insmed Slides: Q1 2026
Insmed has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Insmed Earnings release: Q1 2026
Insmed released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
— Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Qua...
Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
— Insmed's Educational Initiative, Suspect Bronchiectasis (Suspect BE), Aims to Elevate Recognition and Diagnosis of Bronchiectasis and Encourage Conversations with a Pulmonologist — — Bronchiectasis ...
Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026
—New Data in Non-Cystic Fibrosis Bronchiectasis Further Define Impact of BRINSUPRI ® on Respiratory Symptoms— —Findings from a Pharmacokinetic Study Continue to Support Further Evaluation of Treprosti...
Insmed to Present at May 2026 Investor Conferences
BRIDGEWATER, N.J., April 30, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor...
Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
BRIDGEWATER, N.J., April 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor...
Insmed discontinues development of skin condition drug after mid-stage study miss
Insmed said on Tuesday it would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage trial.
Insmed Provides Clinical Update on Phase 2b CEDAR Study
—Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program— —Safety Was Consistent with Previous Studies and No New Safety Signals Were Identified for Either Dose...
Insmed Proxy statement: Proxy filing
Insmed filed a proxy statement on April 1, 2026, providing details for shareholder voting and corporate governance matters.
Insmed Proxy statement: Proxy filing
Insmed filed a proxy statement on April 1, 2026, providing details for shareholder voting and corporate governance matters.
Insmed Slides: Investor presentation
Insmed has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
Insmed Transcript: Study result
The ENCORE phase III trial showed ARIKAYCE plus standard therapy significantly improved respiratory symptoms and culture conversion rates in newly diagnosed or recurrent MAC lung infection, with a favorable safety profile and lower discontinuation rates. These results support regulatory submissions for label expansion and could establish ARIKAYCE as a new standard of care.
Insmed Press release: Study result
Insmed issued a press release on March 23, 2026, disclosing material business information to investors.